AxoGen (AXGN) Set to Announce Earnings on Monday

AxoGen (NASDAQ:AXGN) is set to announce its earnings results after the market closes on Monday, October 29th. Analysts expect the company to announce earnings of ($0.13) per share for the quarter.

AxoGen (NASDAQ:AXGN) last released its quarterly earnings data on Wednesday, August 1st. The medical equipment provider reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.01). The business had revenue of $20.58 million during the quarter, compared to analysts’ expectations of $21.25 million. AxoGen had a negative return on equity of 26.50% and a negative net margin of 24.96%. AxoGen’s quarterly revenue was up 35.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.04) earnings per share. On average, analysts expect AxoGen to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

NASDAQ:AXGN opened at $32.72 on Friday. The stock has a market capitalization of $1.29 billion, a price-to-earnings ratio of -105.55 and a beta of -0.39. AxoGen has a 12-month low of $19.85 and a 12-month high of $56.85.

A number of research analysts have issued reports on AXGN shares. Cantor Fitzgerald restated a “buy” rating and issued a $45.00 target price on shares of AxoGen in a report on Thursday, August 9th. BidaskClub lowered shares of AxoGen from a “buy” rating to a “hold” rating in a report on Saturday, September 8th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $44.67.

In other news, Director Amy Mcbride Wendell bought 5,000 shares of AxoGen stock in a transaction on Tuesday, August 14th. The shares were bought at an average cost of $36.89 per share, for a total transaction of $184,450.00. Following the acquisition, the director now owns 18,333 shares in the company, valued at $676,304.37. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 7.86% of the stock is currently owned by corporate insiders.

About AxoGen

AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Read More: How Do Tariffs Affect Trade Balances?

Earnings History for AxoGen (NASDAQ:AXGN)

Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with's FREE daily email newsletter.

Leave a Reply